Experiencing the Risks of Overutilizing Opioids Among Patients With Chronic Noncancer Pain in Ambulant Care

Conditions

R52.1 M54.9

Wegwarth O, Spies C, Ludwig WD, Donner-Banzhoff N, Jonitz G, Hertwig R.

2022-10-263 citations

Patients’ self‐reported physical and psychological effects of opioid use in chronic noncancer pain—A retrospective cross‐sectional analysis

Erika Schulte, Claudia Spies, Claudia Denke, Joerg J Meerpohl, Norbert Donner‐Banzhoff et al. (9 authors)

European Journal of Pain2021-09-305 citations

10.1002/ejp.1868

Experiencing the risk of overutilising opioids among patients with chronic non-cancer pain in ambulatory care (ERONA): the protocol of an exploratory, randomised controlled trial

Odette Wegwarth, Claudia Spies, Erika Schulte, Joerg J Meerpohl, Christine Schmucker et al. (12 authors)

BMJ Open2020-09-016 citations

10.1136/bmjopen-2020-037642

Interventions

Group 1: After first querying half of the participants of each of the four study populations (general practitioners, doctors specialized in 'special pain management', patients with chronic, noncancer

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: A. Study population for testing the comprehensibility of questionnaires and study materials (comprehension pilot) (N = 40): A1. Patients with chronic (=3 month) noncancer pain: n = 20 A2. Family physicians licensed for narcotic prescriptions (BtM) and physicians specialized in special pain therapy: n = 10 A3. Pharmacists licensed for narcotic substances: n = 10 Data from this comprehension pilot is not evaluated in a confirmatory manner. B. Study population for the RCT (N = 1.200): B1. Family physicians licensed for narcotic prescriptions (BtM): n = 300 B2. Physicians specialized in "Special pain management": n = 300 B3. Patients with chronic (=3 month) noncancer pain: n = 300 B4. Pharmacists licensed for narcotic substances: n = 300 All four study populations will be examined with an identical methodological design (pre-/post-intervention online survey).

Exclusion criteria

Exclusion criteria: Study population 1: Family physicians NOT licensed for prescribing narcotic substances Study population 2: Physicians NOT specialized in "Special pain management" Study population 3: - Patients with tumor-related chronic pain - Patients with chronic noncancer pain = 3 months Study population 4: Pharmacists NOT licensed for narcotic substances such as opioids

Design outcomes

Primary

Measure	Time frame
(i) Objective risk perception; (ii) subjective risk perception; (iii) risk behavior (physicians' prescription behavior; patients' intake behavior; pharmacists counseling behavior)	—

Secondary

Measure	Time frame
(i) differences in risk perception and behavior as a function of how a person learnt about the risks; (ii) differences in risk perception and behavior as a function of an individual’s medical risk literacy; (iii) concordance between actual risk behavior reported at 9-months follow-up and intended change in risk behavior reported immediately after the intervention	—

Countries

Germany

Contacts

Public ContactOdette Wegwarth

Max-Planck-Institut für BildungsforschungCenter for Adaptive Rationality

wegwarth@mpib-berlin.mpg.de00493982406222

Outcome results

None listed